Spinraza Plus Zolgensma Offers Little Extra Benefit in Type 1, Study Suggests episode artwork

EPISODE · Jan 31, 2022 · 7 MIN

Spinraza Plus Zolgensma Offers Little Extra Benefit in Type 1, Study Suggests

from The Spinal Muscular Atrophy Podcast with Kevin Schaefer · host SMA News Today

SMA News Today’s multimedia associate, Price Wooldridge, reads an article about how a small group of children given the gene therapy after Spinraza's start showed only slight further gains; early treatment most important.Also, in her latest vlog DeAnn Runge explores the topic of furry friends. Pets are an important aspect of her life. She explains how she feels pets can benefit the lives of anyone living with SMA. Watch here: https://youtu.be/9Etax9E4cH0 Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/.

Episode metadata supplied by the publisher feed · Published Jan 31, 2022

Embed this episode

Ready to play

Spinraza Plus Zolgensma Offers Little Extra Benefit in Type 1, Study Suggests

0:00 7:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Spinal Muscular Atrophy Podcast with Kevin Schaefer?

This episode is 7 minutes long.

When was this The Spinal Muscular Atrophy Podcast with Kevin Schaefer episode published?

This episode was published on January 31, 2022.

Can I download this The Spinal Muscular Atrophy Podcast with Kevin Schaefer episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!